Alyce Katayama
Professional Bio
Alyce Katayama had more than 30 years of experience representing both institutional and individual clients on a wide range of business issues in the health care industry. She dealt regularly with issues surrounding the 340B Drug Discount Program and the Sunshine Act.
PhRMA 2-0 in The Orphan Drug Wars
To Be or Not to 340B Blog ·
Breaking Down the Proposed Omnibus Guidance – Child Sites
To Be or Not to 340B Blog ·
Breaking Down the Proposed Omnibus Guidance – Covered Entity Eligibility, Registration & Termination
To Be or Not to 340B Blog ·
The Proposed 340B Drug Pricing Program Omnibus Guidelines Have Landed
To Be or Not to 340B Blog ·
Finally! HRSA Proposes Manufacturer Civil Monetary Penalties
To Be or Not to 340B Blog ·